Allergy medication recalled over potentially ‘life-threatening’ cross-contamination
The FDA has issued a nationwide recall of generic Zyrtec tablets after discovering potential cross-contamination with a heartburn drug.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A nationwide recall has been issued for certain lots of allergy medication across the United States. According to reports from the FDA and news outlets like CBS News and WDEF, the recall was triggered by the risk of cross-contamination involving a heartburn medication. The specific products affected are generic Zyrtec tablets, also identified in coverage from WSB-TV and Facebook as Cetirizine Hydrochloride. The contamination involves the drug ranitidine, which was found in the antihistamine tablets, creating a potential health risk for consumers using the medication. Extensive coverage from outlets including Fox Business and The Hill emphasizes that this drug mix-up could lead to reactions described as potentially life-threatening.
Citeline Insights and qz.com specifically identify ranitidine as the contaminant present in the cetirizine tablets. Further reports from USA Today and the Houston Chronicle alert the public to check their medication bottles to see if they possess the affected products. The scope of the recall is national, meaning that the potentially contaminated lots may have been distributed to pharmacies and consumers throughout the entire U.S. market. This situation is critical because the presence of an unintended medication in an allergy treatment can cause severe adverse reactions. According to Yahoo and 13newsnow.com, the cross-contamination of one medication by another could be deadly in certain circumstances.
While coverage does not specify the exact number of bottles or the specific lot numbers affected, the urgency of the recall is underscored by the FDA's involvement and the wide array of reporting from local news stations such as News4JAX, 10TV, and iHeart, all of which focused on the potential danger to patient safety. Moving forward, consumers are urged to follow the guidance provided by the FDA and review the list of affected products mentioned in reports from USA Today. The primary focus remains on the identification and removal of the cross-contaminated cetirizine and ranitidine lots from the supply chain. Coverage indicates that the public should check their current medications immediately. Further updates will likely center on the specific batches involved and any further instructions from health officials regarding the disposal or return of the recalled generic Zyrtec tablets.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 111d ago.
Quick answers
Which medication is being recalled?
Generic Zyrtec tablets, also referred to as Cetirizine Hydrochloride, are being recalled.
What is the cause of the recall?
The recall was triggered by the risk of cross-contamination with ranitidine, a heartburn medication.
What are the potential risks associated with this contamination?
According to Fox Business and The Hill, the drug mix-up could trigger potentially life-threatening reactions.
Where is the recall taking place?
The recall is occurring nationwide across the United States.
Coverage (15)
- Antihistamine recall across the U.S. triggered by heartburn drug contamination risk, FDA says WDEF · 115d ago
- Common antihistamine recalled over potentially dangerous contamination Houston Chronicle · 115d ago
- Antihistamine recall across the U.S. triggered by heartburn drug contamination risk, FDA says CBS News · 115d ago
- Allergy medication recalled as some lots may be cross-contaminated with another medication 13newsnow.com · 115d ago
- Generic Zyrtec tablets recalled over ranitidine contamination qz.com · 115d ago
- Allergy medication recalled over possible drug mix-up that could trigger 'life-threatening' reactions Fox Business · 115d ago
- Allergy medication recalled nationwide over contamination concerns News4JAX · 115d ago
- Ranitidine Contaminates Cetirizine In US Recall insights.citeline.com · 115d ago
- Contamination of one antihistamine by another could be deadly. There’s a recall Yahoo · 115d ago
- Allergy medication recalled as some lots may be cross-contaminated with another medication 10TV · 115d ago
- Allergy Medication Recalled Over Potential Cross-Contamination iHeart · 115d ago
- FDA recalls Cetirizine tablets due to ranitidine cross-contamination. Check your medication now. facebook.com · 115d ago
- Recall alert: Cetirizine Hydrochloride recalled over cross-contamination WSB-TV · 115d ago
- Bottles of antihistamine tablets recalled. See the affected products USA Today · 115d ago
- Allergy medication recalled over potentially ‘life-threatening’ cross-contamination The Hill · 115d ago
Topics
Related trends
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.